Incyte CEO and leadership

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015.

During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Ms. Stamoulis is Incyte’s Chief Financial Officer. Prior to joining Incyte, Ms. Stamoulis was Unum's President and CFO. In this role, she led Unum's strategic and financing activities and was responsible for the finance, corporate strategy, business development, legal, investor relations and corporate communications functions. Ms. Stamoulis led Unum's IPO as well as the Company’s $645M partnership with Seattle Genetics and $65M Series B financing round, which helped transform Unum from a very early-stage startup into a dynamic, well-capitalized, clinical-stage company. Prior to Unum, she was the SVP of Corporate Strategy and Business Development at Vertex and a member of Vertex's Executive Team. She helped develop Vertex's corporate vision of the future and led the development of strategies and initiatives to achieve this vision. She also led the identification, evaluation and execution of key business collaborations to enable Vertex to achieve its strategic objectives and position the company for sustainable long-term growth. Prior to joining Vertex, she spent nearly 15 years in the investment banking and management consulting industries. She was a Managing Director at Citigroup’s Investment Banking division and led the building of the firm’s Life Sciences group. Prior to Citigroup, she was in the Healthcare Investment Banking Group at Goldman Sachs, where she spent the majority of her investment banking career. As an investment banker, she advised clients and led the execution of M&A and capital raising deals with aggregate value in excess of $100 billion.Ms. Stamoulis currently serves as a director of the Board of Hologic, a leading global developer and supplier of diagnostic products, medical imaging systems and surgical products and is a member of the Audit Committee.Ms. Stamoulis started her professional career as a strategy consultant at The Boston Consulting Group where she advised clients on major strategy and organizational change initiatives.

Dashyant Dhanak are an Exec VP/Chief Scientific Ofcr at INCYTE CORP. They have worked as Vp & Head:Discovery Sciences at Janssen Research & Development LLC. Dashyant work or have worked as Vp & Head:Cancer Epigenetics Discovery at Glaxosmithkline PLC. They studied at University of Manchester, Northwestern University, and University of London.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015.

During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.